CHARLOTTE, N.C., Nov. 12, 2020 /PRNewswire-PRWeb/ -- cbdMD,
Inc. (NYSE American: YCBD, YCBD PR A) (the "Company"), one of the
leading, and most highly trusted and recognized cannabidiol (CBD)
brands, announced today an expansion of its topical product line
with the launch of 'Premium Relieve', a product that combines the
pain-fighting power of Lidocaine with Superior Broad Spectrum CBD
extracts – leading to total wellness in one unique topical
formula.
Available in a roll-on applicator or spray, Premium Relieve
combines the proven powers of Lidocaine (4%) with cbdMD's Superior
Broad Spectrum formula, providing temporary relief from minor
muscle aches and pains.
Premium Relieve joins a diverse offering of topical products
featuring high profile over-the-counter (OTC) pain relief
ingredients fused with cbdMD's unique hemp extract blend,
including:
Premium Freeze Pain Relieving Formula ('2020 Product of the
Year' Winner: CBD Topical) - cbdMD's award-winning Freeze gel
offers the proven pain-relief properties of menthol, blended with
the power of domestically sourced CBD, to provide temporary pain
relief while working to ease aching muscles and joints.
Premium Recover Pain Relieving Formula - cbdMD's Recover
combines pain-relieving agent Histamine Dihydrochloride (0.05%)
with the whole-body benefits of cbdMD's Superior Broad Spectrum CBD
formula into a unique, richly moisturizing cream that's great for
temporary relief of pain and muscle aches, without any of the
smell.
cbdMD's release of Premium Relieve marks an advancement in the
topical market as it is one of the few CBD topicals available in
aerosol spray form, utilizing a unique Bag-on-Valve Technology that
allows for spraying at any angle and covering difficult-to-reach
areas. In addition, Premium Relieve contains the most abundant CBD
content of any Lidocaine-infused topical currently on the
market.
"Topicals have never been more popular for consumers, with more
and more products adding CBD to their formulas these days," said
Ken Cohn, Chief Marketing Officer at
cbdMD. "At cbdMD, we're revolutionizing the topical market by
introducing innovative products that continue to lead in each
category. With 'Premium Relieve', we are proud to now offer an
expanded topicals line that is well-rounded and balanced, with
broad appeal to not only health-minded individuals, but anyone
seeking to enhance their personal wellness."
To learn more about cbdMD and their comprehensive line of U.S.
grown, non-THC1 CBD oil products, please visit:
http://www.cbdmd.com.
About cbdMD, Inc.
cbdMD, Inc. is one of the leading, most highly trusted, and most
recognized cannabidiol (CBD) brands, whose current products include
CBD tinctures, CBD capsules, CBD gummies, CBD topicals, CBD bath
bombs and CBD pet products. cbdMD is also a proud partner of
Bellator MMA and Life Time, Inc., and has one of the largest
rosters of professional sports athletes who are part of "Team
cbdMD." To learn more about cbdMD and our comprehensive line of
over 100 SKUs of U.S. produced, Non-THC[1] CBD products, please
visit http://www.cbdMD.com, follow cbdMD on Instagram and Facebook,
or visit one of the 6,000 retail outlets that carry cbdMD
products.
Forward-Looking Statements
This press release contains certain forward-looking statements that
are based upon current expectations and involve certain risks and
uncertainties within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Such forward-looking statements can
be identified by the use of words such as ''should,'' ''may,''
''intends,'' ''anticipates,'' ''believes,'' ''estimates,''
''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and
''proposes.'' These forward-looking statements are not guarantees
of future performance and are subject to risks, uncertainties, and
other factors, some of which are beyond our control and difficult
to predict and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements,
including, without limitation, statements made with respect to the
expansion of the consumer market for CBD products and our ability
to increase our market share, our limited operating history, our
ability to expand our business and significantly increase our
revenues, our ability to effectively leverage our brand
partnerships and sponsorships, our ability to effectively compete
in our market, our ability to achieve our net sales guidance, and
our ability to report profitable operations in the future. You are
urged to carefully review and consider any cautionary statements
and other disclosures, including the statements made under the
heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K
for the fiscal year ended September 30,
2019 as filed with the Securities and Exchange Commission
(the "SEC") and our other filings with the SEC. All forward-looking
statements involve significant risks and uncertainties that could
cause actual results to differ materially from those in the
forward-looking statements, many of which are generally outside the
control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc.
does not undertake any duty to update any forward-looking
statements except as may be required by law. The information which
appears on our websites and our social media platforms, including,
but not limited to, Instagram and Facebook, is not part of this
press release.
1 Non-THC is defined as below the level of detection using
validated scientific analytical tools.
Contact:
PR:
cbdMD, Inc.
Lauren Greene
Communications Specialist
Lauren.Greene@cbdMD.com
(843) 743-9999
Investors:
cbdMD, Inc.
John Weston
Director of Investor Relations
John.Weston@cbdMD.com
(704) 249-9515
Media Contact
Lauren Greene (PR), cbdMD, (843)
743-9999, Lauren.Greene@cbdMD.com
John Weston (Investors), cbdMD,
(704) 249-9515, John.Weston@cbdMD.com
SOURCE cbdMD